Home・Listă Acțiuni・Eli Lilly and Co.

Eli Lilly and Co.

Deschisă

SectorSănătate

1,190.47 1.78

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1154.56

Maxim

1229.94

Indicatori cheie
By Trading Economics
Venit	758M 7.4B
Vânzări	507M 20B
P/E Medie Sector	39.835 68.51
EPS	8.55
Randament dividend	0.54
Marjă de profit	37.355
Angajați	50,000
EBITDA	1.3B 9.7B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+16.79% upside

Dividende
By Acuity
Randament dividend Medie Sector	0.54% 2.29%
Următoarele câștiguri	29 oct. 2026
Data viitoare de dividende	10 sept. 2026
Următoarea dată ex-dividende	14 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	249B 1T
Deschiderea anterioară	1188.69
Închiderea anterioară	1190.47

Sentimentul știrilor

By Acuity

42%

58%

133 / 340 Clasament în Healthcare

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 aug. 2026, 23:42 UTC

News

Eli Lilly reported second-quarter revenue of $23 billion, raising its full-year guidance to $85 billion to $87 billion. Shares are higher in after-market trading.

4 aug. 2026, 23:02 UTC

Eli Lilly shares are higher in after-market trading, driven by a broader market rally and optimism surrounding potential oil supply agreements.

3 aug. 2026, 20:03 UTC

News

Social Media

Event

Eli Lilly's shares are declining amid negative sentiment despite expanding access to its obesity drug retatrutide and receiving FDA designation for olomorasib.

31 iul. 2026, 23:06 UTC

Eli Lilly and Co shares are higher in after-market trading, though they remain below their 20-day moving average by 2.91%. No specific news was identified.

30 iul. 2026, 21:01 UTC

Eli Lilly shares are higher in after-market trading, recovering from an earlier dip. Broader market sentiment remains positive amid geopolitical tensions and inflation concerns.

29 iul. 2026, 23:26 UTC

Eli Lilly and Co shares are lower in after-market hours amid unusual trading activity. Broader market volatility follows the Federal Reserve's interest rate decision.

28 iul. 2026, 22:06 UTC

Eli Lilly shares are lower in after-market hours, with no specific news identified. Broader market trends may be impacting sentiment following declines in the Nikkei 225 Index.

27 iul. 2026, 23:16 UTC

Eli Lilly and Co shares are lower in after-market hours, continuing a decline since Monday's close amid a broader market downturn. No specific news was identified.

24 iul. 2026, 23:41 UTC

Eli Lilly and Co shares declined in after-market trading, experiencing notable fluctuations without any specific news to explain the price action.

23 iul. 2026, 10:06 UTC

Social Media

Eli Lilly shares are lower in pre-market trading, nearing the $1074–$1003 support zone. Broader market declines coincide with traders awaiting the ECB's interest rate decision.

22 iul. 2026, 23:16 UTC

Social Media

Eli Lilly acquires ATAI for $2.8 billion, entering the psychedelic medicine sector. Shares are higher in after-market trading following the announcement.

21 iul. 2026, 20:07 UTC

Social Media

News

Eli Lilly is higher today, supported by overall market strength and plans to defend against a lawsuit from Novo Nordisk over its weight-loss drugs.

20 iul. 2026, 23:16 UTC

Eli Lilly's shares are roughly flat in after-market trading, amid rising treasury yields and geopolitical tensions affecting interest-sensitive sectors like pharmaceuticals.

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

16.79% sus

Prognoză pe 12 luni

Medie 1,366.26 USD 16.79%

Maxim 1,600 USD

Minim 1,135 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

21 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 21 analiști care au acordat evaluări ale acțiunilor Eli Lilly and Co. - Dist în ultimele 3 luni.

Sentiment

By Acuity

133 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.